Prospective multicenter study of first-line inetetamab-based combination therapy for HER2-positive advanced biliary tract cancer (ESMO Asia 2026) - Oct 1, 2026 - Abstract #387eP; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • Combination therapy • Metastases • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor • HER-2
|
|
Feng Xie; Zhu Ke Lei; Liukang Tang; Yuting Zheng; Binghua Dai
|